(Q44182167)

English

Acute interferon beta-1b administration alters hypothalamic-pituitary-adrenal axis activity, plasma cytokines and leukocyte distribution in healthy subjects

scientific article published in November 2002

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

Acute interferon beta-1b administration alters hypothalamic-pituitary-adrenal axis activity, plasma cytokines and leukocyte distribution in healthy subjects (English)

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

author name string

Goebel MU

1

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

Baase J

2

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

Pithan V

3

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

Exton M

4

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

Saller B

5

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

Schedlowski M

6

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

Limmroth V

7

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

publication date

1 November 2002

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

Psychoneuroendocrinology

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

27

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

8

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

881-892

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

Human fibroblast interferon for clinical trials: pharmacokinetics and tolerability in experimental animals and humans.

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2801%2900099-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Early depressive symptoms in cancer patients receiving interleukin 2 and/or interferon alfa-2b therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2801%2900099-3

7 January 2021

based on heuristic

inferred from DOI database lookup

The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2801%2900099-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Interferon beta for multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2801%2900099-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Changes in plasma cytokines induced by interferon-beta1a treatment in patients with multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2801%2900099-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Interferon-β treatment in multiple sclerosis patients decreases the number of circulating T cells producing interferon-γ and interleukin-4

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2801%2900099-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Interferon beta-1b serum levels in multiple sclerosis patients following subcutaneous administration

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2801%2900099-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Acute effects of interferon beta-1a on plasma cytokine levels in patients with MS

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2801%2900099-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Management of patients receiving interferon beta-1b for multiple sclerosis: report of a consensus conference

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2801%2900099-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Amelioration of flulike symptoms at the onset of interferon β- 1b therapy in multiple sclerosis by low-dose oral steroids is related to a decrease in interleukin-6 induction

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2801%2900099-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of interferon-beta1b on magnetic resonance imaging outcomes in secondary progressive multiple sclerosis: results of a European multicenter, randomized, double-blind, placebo-controlled trial. European Study Group on Interferon-beta1b in secon

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2801%2900099-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Can we predict flu-like symptoms in patients with multiple sclerosis treated with interferon-beta?

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2801%2900099-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Managing side effects of interferon-beta in patients with relapsing-remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2801%2900099-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Side effect profile of interferon beta-1b in MS: results of an open label trial

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2801%2900099-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Short-term treatment of relapsing remitting multiple sclerosis patients with interferon (IFN)-beta1B transiently increases the blood levels of interleukin (IL)-6, IL-10 and IFN-gamma without significantly modifying those of IL-1beta, IL-2, IL-4 and

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2801%2900099-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of cytokines on the pituitary-adrenal axis in cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2801%2900099-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2801%2900099-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of IFNbeta and anti-IFNbeta antibodies on NK cells in multiple sclerosis patients

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2801%2900099-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Low-dose steroids reduce flu-like symptoms at the initiation of IFNbeta-1b in relapsing-remitting MS.

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2801%2900099-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Acute interferon-alpha administration modulates sucrose consumption in the rat.

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2801%2900099-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2801%2900099-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Regulation of the hypothalamic-pituitary-adrenal axis by cytokines: actions and mechanisms of action

1 reference

https://api.crossref.org/works/10.1016%2FS0306-4530%2801%2900099-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0306-4530(01)00099-3

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44182167&oldid=2108317429"